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Abstract
Background Folate-associated one-carbon metabolism
(FOCM) is an important pathway in colorectal neoplasia
risk but data on genetic variation in this pathway are lar-
gely limited to studies of single SNPs in selected genes.
Methods We used a comprehensive tagSNP approach to
study the association between genetic variation in 11 genes
in the FOCM pathway and risk of incident distal colorectal
adenomas in a sigmoidoscopy-based case–control study.
We included 655 cases (one or more adenomas) and 695
controls (no adenomas) recruited from one of two Kaiser
Permanente clinics between 1991 and 1995. We assessed a
total of 159 tagSNPs selected using Haploview Tagger as
well as selected non-synonymous SNPs. We used uncon-
ditional logistic regression to model the association
between SNPs and risk of distal adenomas, assuming a log-
additive model.
Results Five SNPs in the SLC19A1 (RFC1) gene:
rs1051266 (G80A), rs283895, rs2236484, rs12482346, and
rs2838958 were associated with adenoma risk after cor-
rection for multiple testing (all corrected p values B0.043).
The non-synonymous SLC19A1 SNP G80A interacted sig-
niﬁcantly with the MTHFR C677T genotype (interaction
p value = 0.018).
Conclusion Our data suggest that genetic variation in
SLC19A1 may modify the risk of distal colorectal adenoma.
Keywords Folate MTHFR SLC19A1 TagSNP Folate 
Colorectal adenoma
Introduction
Folate-associated one-carbon groups are essential for hun-
dreds of intracellular transmethylation reactions including
those involved in DNA methylation and DNA synthesis [1].
An inverse association between folate intake and carcino-
genic changes in colorectal epithelium has been observed,
both in vitro and in vivo, in both humans and animals [1–3].
However,clinicaltrialsoffolicacidsupplementation[4]and
animalexperiments[5,6]suggestthatfolateplaysadualrole
in the colorectum by both protecting against and promoting
growth of neoplastic lesions depending on timing, dose, and
source (diet vs. supplements).
Folate-associated one-carbon metabolism (FOCM) is a
complex cycle of inter-related reactions that provide one-
carbon groups needed for numerous intracellular processes.
This pathway has been well characterized, and a mathe-
matical model has been developed [7, 8]. Genetic variants
in genes that play key roles in the FOCM pathway have
been investigated as potential colorectal adenoma suscep-
tibility genes, but studies have been limited to one or a few
SNPs and a small number of genes, with mixed results
[9, 10]. The MTHFR C677T and A1298C polymorphisms
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risk [11, 12]. A recent study of genetic variability in
FOCM-related genes and adenoma risk focused on 24 non-
synonymous SNPs in 13 genes, reported little evidence of a
major role for the folate pathway genes included in their
analysis [13].
In this study, we conducted a comprehensive analysis of
the role of genetic variation in 11 genes that play key roles
in the FOCM pathway and colorectal adenoma risk.
Figure 1 deﬁnes the genes included in the current analysis
and their roles in FOCM. We included enzymes involved in
the uptake of folate, nucleotide synthesis, and S-adeno-
sylmethionine (SAM) synthesis. We also included the gene
for cystathionine-b-synthase (CBS), an enzyme important
for modulating intracellular homocysteine and that for
gastric intrinsic factor (GIF), which is involved in the
uptake of vitamin B12, a key co-factor in FOCM.
Materials and methods
Study subjects
The subjects in this study were participants in the USC/
Kaiser Permanente study of risk factors for colorectal
adenomas. Characteristics of this study population have
been previously described [14, 15]. Brieﬂy, phase 1 sub-
jects were recruited from one of two Kaiser Permanente
clinics and received a sigmoidoscopy examination from
1991 to 1993, while phase 2 subjects were recruited from
the same two clinics from 1993 to 1995. Identical criteria
were used to recruit subjects from each phase. Eligible
subjects were English-speaking, between the ages of
50–74 years, and living in the Los Angeles metropolitan
area. Subjects were excluded if they had a history of
invasive cancer, inﬂammatory bowel disease, familial
polyposis, previous bowel surgery, or symptoms suggestive
of gastrointestinal disease. Cases were those subjects who
had at least one histologically conﬁrmed adenoma during
their sigmoidoscopy exam, and controls were those sub-
jects with no evidence of an adenoma at sigmoidoscopy
and who had no history of conﬁrmed adenomas. Cases
were individually matched to controls on age (within
5 years), gender, sigmoidoscopy date (within 3 months),
and Kaiser Permanente clinic. All subjects signed an
approved informed consent, donated a blood sample, and
ﬁlled in two questionnaires.
Risk factor data
The risk factor questionnaire queried demographic infor-
mation, family cancer history, smoking history, history of
Fig. 1 Genes involved in folate-associated one-carbon metabolism.
Abbreviations: CBS cystathionine-b-synthase, DHFR dihydrofolate
reductase,FOLR1folatereceptorisoform1,GIFgastricintrinsicfactor,
MAT2A methionine adenosyltransferase isoform 2 (non-liver),
MTHFD1 methylenetetrahydrofolate dehydrogenase/methynltetra-
hydrofolatecyclohydrolase/formyltetrahydrofolate synthetase, MTHFR
methylenetetrahydrofolate reductase, MTR methionine synthase, SHMT
serine hydroxymethyltransferase, SLC19A1 solute carrier family 19
(folate transporter) member 1 (also called the reduced folate carrier 1
(RFC1)), TYMS thymidylate synthase
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aspirin and other non-steroidal anti-inﬂammatory agents,
laxatives), speciﬁed dietary supplements (multivitamins,
calcium), a physical activity history, a history of usual sun
exposure, a brief description of their usual method for
cooking red meats, and, for women, a brief reproductive
history. A separate food frequency questionnaire (FFQ) was
used to estimate nutrient intake. For phase 1 subjects, we
used a modiﬁed form of the Block food frequency ques-
tionnaire [16]. For phase 2 subjects, we used a diet ques-
tionnaire developed and validated at the University of
Hawaii [17]. The two questionnaires were similar with
respect to the number and type of foods queried and the
method for estimating nutrient intakes, in grams, milli-
grams, or micrograms per day, as appropriate for the nutri-
ent. Nutrient intakes were based on expected nutrient levels
for the stated portion size and estimated consumption fre-
quency per week for speciﬁc foods and supplements using
thenutritionistfoodandsupplementdatabasesdeveloped by
the designers of the FFQs. Dietary folate intake was cate-
gorized into quartiles using study phase-speciﬁc cutpoints
and intakes from the controls. For alcohol, we used pre-
deﬁned cutpoints of 0, 0.1–10, 11–20, and[20 g/day.
Plasma folate
Blood samples were taken from fasting subjects into
EDTA-coated tubes in the morning and immediately put on
ice until processing to separate the plasma. In both study
phases, samples were stored at -70C until processing. For
phase 1 subjects, plasma folate was determined for the ﬁrst
370 male subjects (52.3%) and the ﬁrst 316 samples female
subjects (86.8%) using the Quantaphase Radioassay as
described [18]. For phase 2 subjects, plasma folate was
estimated for 335 men (97.7%) and 199 women (97.5%)
using the Quantaphase Radioassay II.
Plasma total homocysteine (tHcy)
Plasma tHcy was not estimated for phase 1 subjects. For
phase 2 subjects plasma tHcy (lmol/L) was estimated for
335 men (97.7%) and 199 women (97.5%). Blood samples
were taken from fasting subjects into EDTA-coated tubes
in the morning and immediately put on ice until processing
to separate the plasma. In both study phases, samples were
stored at -70C until processing. For determination of
plasma tHcy, we used the reversed-phase HPLC method of
Kuo et al. [19]. All chemicals were purchased from Sigma.
Plasma thiols were measured using ﬂuorescence detection
after derivatization with ammonium 7-ﬂuorobenzo-2-oxa-
1,3-diazole-4-sulfonate (SBDF). HPLC separation was
carried out using gradient analysis with ﬂuorescence
detection (Varian Assoc., Sugar Land Texas) and the
Agilent Technology HPLC 1100 system (Agilent Tech-
nology, Wilmington DE). Thiols were separated using a
Bakerbond C18 4.6 9 250 mm column (Mallinckrodt
Baker, Phillipsburg, NJ). The mobile phase consisted of
8% methanol to 40% at time 12 min. For quality control
purposes, pooled plasma samples were analyzed with each
batch of samples. The intra-assay coefﬁcient of variance
was 5.7% and inter-assay CV was 4.4% (8.6 lM).
SNP selection
We used a comprehensive tagSNP approach to assess gene-
level risk in a pre-folic acid-fortiﬁcation population of
colorectal adenoma patients and controls. Supplemental
Table 1 describes the SNPs included in this analysis by
race/ethnic group. SNPs were selected using Haploview
Tagger [20] and based on the CEPH data using the fol-
lowing criteria: MAF C 5%, pairwise r
2 C 0.95, and
distance from closest SNP greater than 60 base pairs on the
Illumina platform. The linkage disequilibrium blocks were
determined using data from HapMap data release #16c.1,
June 2005, on NCBI B34 assembly, dbSNP b124. For each
gene, we extended the 50- and 30-UTR regions to include
the 50- and 30-most SNP within the LD block (approxi-
mately 10 kb upstream and 5 kb downstream). In regions
of no- or low-LD, SNPs with an MAF C 5% at a density of
approximately 1 per kb were selected from either HapMap
or dbSNP. Finally, non-synonymous and expert-curated
SNPs regardless of MAF were included. The SNPs inclu-
ded in this study are listed in Supplementary Table 1.
SNP genotyping
Except for the MTHFR C677T polymorphism (described
later), SNPs were genotyped on the Illumina GoldenGate
platform [21]. We implemented a series of quality control
checks based on Illumina metrics, and SNPs were excluded
from analysis based on the following criteria: GenTrain
score\0.4, 10% GC score\0.25, AB T Dev[0.1239,
call rate\0.95, more than 2 Mendelian errors[2o r
discordance with HapMap[3. Inter- and intraplate repli-
cates were included, and SNPs were excluded from the
analysis if there were greater than 2 errors on replicate
genotypes. In addition, genotype data from 30 CEPH trios
(Coriell Cell Repository, Camden, NJ) were used to con-
ﬁrm reliability and reproducibility of the genotyping. SNPs
were excluded from the analysis if more than 3 discordant
genotypes were discovered in comparison with genotypes
from the International HapMap Project [22]. After deleting
SNPs with a minor allele frequency\0.05 in the total
study sample and those with a p value for Hardy–Weinberg
equilibrium (HWE)\0.0003 (the Bonferroni-corrected
p value), we calculated effect estimates for 159 SNPs.
Cancer Causes Control (2011) 22:541–552 543
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We have previously reported on associations between
folate and the MTHFR C677T genotype on adenoma risk in
the phase 1 subjects [23]. For phase 1 subjects, the MTHFR
C677T genotype (rs1801133) was determined by the PCR–
RFLP method of Frosst et al. [24] using their published
primer pairs. MTHFR 677 genotyping was not available for
14 phase 1 subjects and 485 phase 2 subjects. For these
subjects, the 677 genotype was determined by imputation
using the MACH software [25]. Accuracy was 97.4% for
non-Hispanic whites, 99.8% for Hispanics, 93.4% for
African Americans, and 94.5% for Asians.
Statistical analysis
Minor allele frequency was estimated from genotype data
from cases and controls combined. Hardy–Weinberg
equilibrium was assessed using a v
2 test. Pairwise linkage
disequilibrium between SNPs was estimated using Haplo-
view [20]. We used the square of the correlation coefﬁcient
(r
2) between markers to deﬁne linkage using the data from
the study population. We have previously established that
using unconditional logistic regression adjusting for the
matching factors led to the same results as conditional
logistic regression while allowing use of the entire study
population [23]. Therefore, we used unconditional logistic
regression controlling for the matching factors (age, sex,
clinic and examination date), study phase and, in non-ethnic
group-speciﬁc analyses, race/ethnic group to estimate main
effects and stratum-speciﬁc odds ratios. Additional control
for dietary folate (mcg/ml), total dietary ﬁber, multivitamin
use (yes/no), and alcohol intake (0, [0–10, 11–20 and
[20 g/day) did not change the results, and we present only
the matching factor, race/ethnicity (where appropriate), and
phase-adjusted models here.
Except for the MTHFR C677T (rs1801133) and MTHFR
A1298C (rs1801131) polymorphisms, for which there are
data supporting a recessive model, we assumed a log-
additive model to assess genotype/adenoma associations.
To minimize population stratiﬁcation, we conducted all
analyses separately by race/ethnic group. Since prior data
suggest speciﬁc effects for MTHFR C677T and A1298C,
p values for these two SNPs were not corrected for multiple
testing in any analysis. Additionally, tests based on prior
data from the literature (e.g., the interaction between
SLC19A1 G80A genotype and MTHFR C677T genotype)
were not corrected for multiple testing. For the log-additive
model and within each gene, p values for all other SNPs
were adjusted for multiple testing taking into account
correlated tagSNPs using a modiﬁed test of Conneely and
Boehnke (pact)[ 26]. The pact also adjusts for the correlation
structure of each gene within each ethnic group, using the
race/ethnic group-speciﬁc data to compute the underlying
correlation structure speciﬁc to that group. For all stratiﬁed
analyses, we included interaction terms in the regression
models to get the interaction p values. p Values for trend
were estimated by entering the quartile value (1–4) into the
regression model. The likelihood ratio test was used to test
for heterogeneity between strata. For these multiple degree
of freedom likelihood ratio tests, the Bonferroni method
was used to reset the signiﬁcance level to 0.0003, based on
a total of 159 SNPs.
We assessed the association between genotype and
plasma tHcy using a multiple regression where plasma
tHcy was modeled as a continuous variable, and the change
in plasma tHcy per each variant allele (e.g., 0, 1, or 2) was
assessed using a 1-df likelihood ratio test, corrected for
multiple testing using the method of Conneely and
Boehnke [26]. Since plasma tHcy is not normally distrib-
uted, it was ﬁrst transformed to its natural logarithm.
Comparisons between cases and controls for selected
baseline characteristics and comparisons between subjects
with and without genotyping data were made using mul-
tiple regression controlling for the matching factors, race/
ethnicity, and study phase. For dietary factors, we also
controlled for calories. All statistical analyses were con-
ducted using the R programming language and SAS v9.1.
Results
Genotyping results were available for a maximum of 1,354
of 1,621 subjects with questionnaire data (83.5%). Phase 2
subjects did not differ from phase 1 subjects in age, gender,
ethnicity, and smoking patterns but had higher estimated
dietary folate and alcohol intakes. The subjects with
genotyping data did not differ signiﬁcantly from those with
no genotyping data on selected adenoma risk factors (data
not shown). Since data on plasma folate was not available
for all subjects, we compared those with data on plasma
folate to those with no data on plasma folate. Those with
plasma folate data differed signiﬁcantly from those with no
plasma folate data on a number of adenoma risk factors
(e.g., dietary folate, total dietary ﬁber, and red meat
intakes), and thus plasma folate was not used in any of the
analyses.
The characteristics of the study population are presented
in Table 1. Cases were more likely to be current smokers
and to drink more alcohol, had less dietary folate and ﬁber
intakes, more saturated fat intake, and ate more red meat.
After adjustment for the matching factors, race/ethnic
group, study phase and calories, smoking, dietary folate,
and ﬁber intakes remained signiﬁcantly different between
cases and controls.
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The per allele associations with adenoma risk (except for
MTHFR C677T and A1298C as noted in the ‘‘Methods’’
section) for all 159 SNPs analyzed, by race/ethnicity, are
shown in Supplemental Table 2. When considering all
subjects combined, we observed 5 SNPs in the SLC19A1
gene that were statistically associated with adenoma risk
Table 1 Selected characteristics of the study population
Variable Controls
n = 696
Cases
n = 655
p Value
a
Age mean (SD)
b 61.59 (6.7) 61.72 (6.9) 0.66
Sex n (% male)
b 458 (65.8) 418 (63.8) 0.42
Race/ethnic group
b
White 372 (53.5) 351 (53.6) 0.32
Black 108 (15.5) 117 (17.9)
Hispanic 73 (10.4) 74 (11.3)
Asian 114 (16.5) 81 (12.4)
Other 29 (4.15) 32 (4.9)
Calories mean (SD) 2,052 (960.7) 2,090 (939.2) 0.14
BMI mean (SD) 27.13 (4.6) 27.51 (4.5) 0.24
Alcohol (g/day) mean (SD)
c,d 7.93 (27.2) 9.78 (29.5) 0.22
Smoking
Never n (%) 283 (42.7) 233 (37.0) \0.01
Former n (%) 314 (47.4) 284 (45.2)
Current n (%) 66 (9.95) 112 (17.8)
Missing/unknown 33 26
Smoking (pack years) mean (SD) 16.85 (32.1) 18.83 (30.5) 0.01
Multivitamin use (% Yes)
b 58.8 57.9 0.64
Dietary B12 (mcg/day) mean (SD)
b,c 6.14 (4.8) 6.09 (4.5) 0.59
Dietary folate (mcg/day) mean (SD)
b,c 367.5 (212.5) 337.0 (181.9) \0.01
Plasma total homocysteine (lmol/L)
b 10.35 (3.75) 10.48 (4.73) 0.74
Total dietary ﬁber g/day mean (SD)
b,c 22.84 (13.3) 21.46 (12.3) \0.01
Vegetable ﬁber g/day mean (SD)
b,c 8.38 (7.05) 7.51 (5.6) \0.01
Saturated fat g/day mean (SD)
b,c 23.45 (13.6) 24.56 (13.6) 0.12
Red meat g/day mean (SD)
b,c 66.21 (67.4) 68.47 (56.1) 0.63
Number of adenomas n (%)
1 698 (89.4)
C2 83 (10.6)
Missing 1
Adenoma size n (%)
\1c m 526 (68.1)
C1c m 247 (31.9)
Missing 9
Adenoma site n (%)
Rectum (\15 cm) 146 (18.8)
Colon (C15 cm) 631 (81.2)
Missing 5
a Comparisons between cases and controls for selected baseline characteristics were made using multiple regression controlling for the matching
factors (age, sex, clinic, and examination date) and study phase
b 1 control was missing sex and age data, 2 controls were missing sex data, and 7 controls and 10 cases were missing data on race/ethnic group.
For phase 2 subjects, 7 controls and 7 cases were missing plasma total homocysteine data
c All dietary intakes were deﬁned as average use in the year before the sigmoidoscopy. Comparisons between cases and controls are adjusted for
the matching factors, study phase, and calorie intake
d Sum of alcohol content of wine (10.9 g/serving), beer (12.8 g/serving), and spirits (15.0 g/serving) in the year before the sigmoidoscopy
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5 SNPs, rs12482346 (OR = 1.24; 95% CI = 1.07–1.44;
pact = 0.032), rs2838958 (OR = 0.79; 95% CI = 0.68–
0.92; pact = 0.02) and rs1051266 (OR = 1.25; 95% CI =
1.07–1.45; pact = 0.028) were in moderate linkage disequi-
librium (LD) in the total study population (rs12482346–
rs2838958, r
2 = 0.63; rs12482346–rs1051266, r
2 = 0.79;
rs2838958–rs1051266, r
2 = 0.69). The remaining 2 tag-
SNPs, rs2838951 (OR = 0.78; 95% CI = 0.67–0.91;
pact = 0.015) and rs2236484 (OR = 1.25; 95% CI = 1.07–
1.46; pact = 0.027), were not in linkage disequilibrium with
these SNPs or each other. Heterogeneity across race/eth-
nicity in the total study population was statistically signiﬁ-
cant for one SNP (MTHFD1 rs11627525; p = 0.0000886).
MTHFD1 rs11627525 was not signiﬁcantly associated with
adenoma risk for any race/ethnic group in the main effects
analysis.
When the analysis was restricted to non-Hispanic
whites, a sixth SNP in the SLC19A1 gene (rs7499) and two
SNPs in the MTHFD1 gene (rs11627387 and rs8016556)
were associated signiﬁcantly with risk (Table 2). SLC19A1
rs7499 is in the same haplotype block as rs1051266.
Among the SNPs signiﬁcant in non-Hispanic whites, there
was nominally signiﬁcant heterogeneity across race/ethnic
group for one SNP (MTHFD1 80116556; p = 0.03).
Compared to those with at least one wild-type allele,
neither theMTHFRC677TTTgenotype (rs1801133) northe
MTHFR A1298C CC genotype (rs1801131) was associated
with adenoma risk; OR = 0.93, 95% CI = 0.66–1.32 and
OR = 0.97, 95% CI = 0.66–1.43 for the 677 TT and 1298
CC genotypes, respectively. Similarly, there were no asso-
ciations between MTR D919G (rs1805087), MTHFD1
R653Q (rs2236225), SHMT1 L474F (rs1979277), or
MTHFRA1793Q(rs2274976)andadenomariskoverallorin
non-Hispanic whites (Supplementary Table 2).
Dietary folate, alcohol, and adenoma risk
We assessed possible modiﬁcations of the genotype/ade-
noma associations by dietary folate intake and alcohol use
for all 159 tagSNPs in the total study population and non-
Hispanic whites. There was no interaction between any
SLC19A1 or MTHFD1 SNP and dietary folate or alcohol in
either the total study population or non-Hispanic whites
(data not shown). The interactions between MTHFR C677T
and A1298C and folate availability and alcohol use,
assuming a recessive model, are shown in Table 3. Sample
size was not sufﬁcient to assess genotype effects for an
index of folate and alcohol combined (there were 3 cells
with fewer than 5 subjects, including cells with 0 subjects,
in MTHFR A1298C and 1 such cell for MTHFR C677T).
For the 677 TT genotype, there was no evidence of a linear
trend across quartiles of dietary folate intake (p value for
trend = 0.793). When we stratiﬁed on alcohol intake, the
OR for the 677 TT genotype and high alcohol consumption
([20 g/day) was non-signiﬁcantly greater than 1.0 (OR =
1.46 (0.60–3.55) and about 1.0 for those drinking 0 g/day
(OR = 0.96 (0.55–1.68), but, again, there was no linear
trend (p = 0.68). For A1298C (rs1801131), there was sig-
niﬁcant heterogeneity across strata of dietary folate
(p = 0.004) due to a signiﬁcant decrease in risk for those in
the second dietary folate quartile (OR = 0.22 (0.07–0.65)
and an increase in risk for those in the highest dietary folate
quartile (OR = 2.07 (0.92–4.64)). In the ﬁrst and third
quartiles, the ORs were 1.27 (0.57–2.85) and 1.15
(0.57–2.33), respectively (p value for linear trend = 0.12).
There was no modiﬁcation by alcohol consumption for
A1298C (heterogeneity p value = 0.98; trend p value =
0.94).
There were no signiﬁcant interactions between any of
the remaining tagSNPs and dietary folate or alcohol (data
not shown). No SNP signiﬁcantly interacted with dietary
B12. However, there was a nominally signiﬁcant interaction
between the vitamin B12 transport protein GIF rs519221
and dietary vitamin B12 (heterogeneity p value = 0.02;
trend p value = 0.003). ORs were less than 1.0 in the
lowest 3 B12 quartiles and non-signiﬁcantly greater than
1.0 in the highest B12 quartile (ORs = 0.63 (0.43–0.92);
0.66 (0.46–0.95); 0.96 (0.67–1.39) and 1.33 (0.89–1.96)
for the lowest intake to the highest intake quartiles,
respectively).
Interactions between FOCM genes and sex
There were no signiﬁcant interactions between any SNPs
and sex at the pre-deﬁned level of signiﬁcance except for
MTHFR A1298C. MTHFR A1298C interacted with sex at a
nominal level of signiﬁcance (interaction p value 0.007).
Assuming a recessive model, the association between
homozygosity for the C allele, compared to those with at
least one A allele, and adenoma risk was signiﬁcantly
decreased in women (OR = 0.50 (0.26–0.96) and non-
signiﬁcantly increased in men (OR = 1.52 (0.92–2.51).
FOCM genes, plasma tHcy, and adenoma risk
The association between SNPs and plasma tHcy was
assessed for phase 2 subjects (data not shown). One SNP in
MTHFR was associated with plasma tHcy at a nominal
level of signiﬁcance (rs9651118; b =- 1.09, ±0.36, pact =
0.03). There were no other associations with plasma tHcy
overall. After stratifying on dietary folate quartiles, there
was no longer an association between rs9651118 and
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Gene/SNP Total
a Non-Hispanic White Black Hispanic Asian p Heterogeneity
SLC19A1
rs2838951
n 1,337 719 221 143 193 0.08
MAF
b 0.37 0.41 0.28 0.35 0.38
OR (95% CI)
c 0.78 (0.67,0.92) 0.70 (0.57, 0.88) 1.28 (0.85, 1.92) 0.97 (0.58,1.62) 0.71 (0.46, 1.09)
pact
d 0.02 0.01 0.97 0.99 0.64
rs2838958
n 1,348 722 224 147 195 0.13
MAF 0.46 0.47 0.27 0.42 0.46
OR (95% CI) 0.79 (0.68, 0.93) 0.73 (0.5, 0.90) 1.30 (0.85, 1.98) 0.85 (0.51, 1.42) 0.75 (0.49, 1.15)
pact 0.02 0.02 0.85 0.99 0.91
rs2236484
n 1,325 712 223 142 188 0.14
MAF 0.46 0.42 0.47 0.47 0.47
OR (95% CI) 1.26 (1.08, 1.47) 1.44 (1.16, 1.79) 0.90 (0.63, 1.28) 0.92 (0.57, 1.49) 1.39 (0.91, 2.13)
pact 0.03 0.01 0.99 0.99 0.90
rs1051266
n 1,344 721 224 146 193 0.68
MAF 0.48 0.45 0.44 0.48 0.47
OR (95% CI) 1.24 (1.06, 1.44) 1.34 (1.08, 1.65) 0.98 (0.68, 1.41) 1.14 (0.71, 1.82) 1.19 (0.79, 1.77)
pact 0.04 0.03 0.99 0.99 0.98
rs12482346
n 1,340 721 222 143 194 0.23
MAF 0.47 0.45 0.49 0.50 0.49
OR (95% CI) 1.24 (1.06, 1.44) 1.42 (1.15, 1.76) 0.88 (0.61, 1.26) 1.06 (0.66, 1.71) 1.19 (0.79, 1.80)
pact 0.04 0.01 0.99 0.96 0.99
rs7499
n 1,334 714 223 144 192 0.35
MAF 0.43 0.41 0.41 0.46 0.46
OR (95% CI) 1.22 (1.04, 1.42) 1.38 (1.11, 1.71) 0.92 (0.64, 1.32) 1.00 (0.62, 1.60) 1.21 (0.79, 1.86)
pact 0.07 0.01 0.99 1.0 1.0
MTHFD1
rs11627387
n 1,346 719 225 147 195 0.24
MAF 0.29 0.31 0.24 0.23 0.29
OR (95% CI) 0.78 (0.66, 0.92) 0.68 (0.54, 0.85) 0.70 (0.45, 1.08) 1.01 (0.57, 1.81) 1.10 (0.71, 1.71)
pact 0.07 0.01 0.96 0.99 0.96
rs8016556
n 1,348 722 225 145 195 0.03
MAF 0.33 0.35 0.26 0.25 0.39
OR (95% CI) 0.87 (0.74, 1.02) 0.69 (0.55, 0.86) 1.32 (0.85, 2.04) 0.84 (0.47, 1.49) 1.20 (0.81, 1.77)
pact 0.67 0.01 0.88 0.99 0.99
a Includes 61 individuals who characterized their race/ethnicity as ‘other’
b Minor allele frequency in cases and controls
c Odds ratio and 95% conﬁdence interval estimated by logistic regression assuming a log-additive (per allele) model and controlling for the
matching factors (age, sex, clinic, and examination date) and study phase. The estimates for the total study population are also adjusted for race/
ethnicity
d Adjusted for multiple testing taking into account correlated tagSNPs using a modiﬁed test of Conneely and Boehnke [26]
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123plasma tHcy in any quartile and no interaction between
dietary folate and genotype (interaction p = 0.67) on
plasma tHcy levels. Neither MTHFR C677T (interaction
p = 0.97, trend p = 0.68) nor MTHFR A1298C (interac-
tion p = 0.98, trend p = 0.87) was associated with plasma
tHcy in any dietary folate quartile. Mean plasma tHcy was
not signiﬁcantly higher for those with the MTHFR 677 TT
or 1298 CC genotypes and low dietary folate compared to
those with the highest dietary folate (data not shown).
There were no signiﬁcant interactions between dietary
folate and genotype for any other SNP (data not shown).
Gene–gene interactions
Gene–gene interactions were assessed for genes for which
therewaspriordatasuggestinginteractionswiththeMTHFR
C677T genotype (Supplemental Table 3). This included
SNPs in CBS, MTR, TYMS, and SLC19A1. In the total study
population,adenomariskperAalleleatSLC19A1rs1051266
was signiﬁcantly increased for those with at least one
MTHFR677Callele(OR = 1.33(1.21–1.56))butriskperA
allele was decreased for those with the 677 TT genotype
(OR = 0.74(0.47–1.17)).Theinteractionpvaluewas0.018.
Nominally signiﬁcant interactions were also observed for 5
other SLC19A1 SNPs (rs17004785, rs2297291, rs3788205,
rs3939250, and rs3827266), none of which were in LD with
rs1051266. There was no interaction between MTR A2756G
(rs1805087) or any CBS SNP and the MTHFR C677T
genotype. There were nominally signiﬁcant interactions
between the MTHFR C677T genotype and 9 SNPs in
MTR (rs12759827, rs10737812, rs1252252, rs4659730,
rs6676866, rs2385511, rs3768150, rs10802569, and rs120
70633) and one SNP in TYMS (rs2298582). Except for
rs12759827 and rs4659730, the remaining seven MTR SNPs
were in LD (r
2[0.70) with each other in non-Hispanic
whites. Only one SNP, rs4659730, was in LD with
rs1805087 and that only in non-Hispanic whites.
Table 3 Association between MTHFR C677T and A1298C genotypes and distal adenoma risk, for the total study population, by dietary folate
and alcohol
Genotype 528–2,191 mcg/day
a,b 360–527 mcg/day 262–359 mcg/day 42–261 mcg/day p Trend p Heterogeneity
Dietary folate quartiles
677TT/677CC 1 CT
c
CC ? CT: cases/controls 124/145 127/149 122/152 187/144 0.70 0.12
TT: cases/controls 14/20 13/24 24/15 17/18
OR (95% CI)
d 0.91 (0.44, 1.9) 0.66 (0.32, 1.36) 2.01 (1.0, 4.05) 0.78 (0.39, 1.6)
1298CC/1298AA 1 AC
AA ? AC: cases/controls 125/158 127/157 152/157 195/162 0.12 0.004
CC: cases/controls 14/20 13/24 24/15 17/18
OR (95% CI) 2.07 (0.92, 4.6) 1.15 (0.57, 2.33) 0.22 (0.07, 0.65) 1.27 (0.57, 2.85)
0 g/day
e 0.1–10 g/day 11–20 g/day [20–600 g/day p Trend p Heterogeneity
Alcohol use
677TT/677CC 1 CT
CC ? CT: cases/controls 265/277 153/196 60/50 80/67 0.52 0.68
TT: cases/controls 26/30 18/29 8/9 16/9
OR (95% CI) 0.96 (0.55, 1.68) 0.83 (0.44, 1.56) 0.69 (0.24, 1.93) 1.46 (0.60, 3.55)
1298CC/1298AA 1 AC
AA ? AC: cases/controls 278/297 163/210 63/53 94/74 0.94 0.98
CC: cases/controls 24/28 18/23 8/6 4/4
OR (95% CI) 0.92 (0.52, 1.64) 1.11 (0.57,2.13) 1.04 (0.33, 3.25) 0.88 (0.21, 3.67)
a Quartile cutpoints were based on the distribution of the controls and were study phase speciﬁc
b Dietary folate values reﬂect reported average intake in the year before the sigmoidoscopy
c Numbers do not add up to total due to missing values for genotype for some whose race/ethnic group classiﬁcation was ‘other’ (27 cases/29
controls for C677T and 2 cases/1 control for A1298C) or alcohol (1 case)
d All ORs and 95% conﬁdence intervals were estimated by unconditional logistic regression assuming a recessive model and adjusting for the
matching factors (age, sex, clinic, examination date), race/ethnic group and study phase
e Alcohol cutpoint values were pre-determined and not based on the population distribution of alcohol consumption
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In this study, we conducted a comprehensive analysis of
159 tagSNPs in 11 genes involved in folate-associated one-
carbon metabolism and the risk of distal colorectal
adenomas. Our results suggest that genetic variability in
SLC19A1 (also known as RFC1) may be associated with
distal colorectal adenoma risk. There was no signiﬁcant
modiﬁcation by dietary folate intake or alcohol for any
SNP except MTHFR A1298C and dietary folate. The data
were consistent with a possible interaction between the
MTHFR 1298 CC genotype and sex. There was a signiﬁ-
cant interaction between SLC19A1 rs1051266 (G80A,
H27R) and the MTHFR C677T genotype. Seven SNPs in
the MTR gene that were within a single LD block among
non-Hispanic whites, also interacted with the MTHFR
C677T genotype.
To our knowledge, this is the most comprehensive study
of genetic variation in the folate pathway and risk of
colorectal adenoma conducted to date. Hazra et al. [13]
assessed the association between 24 non-synonymous
SNPs in 13 folate pathway genes and colorectal adenoma
risk in the Nurses’ Health Study. They reported a signiﬁ-
cant association only for the transcobalamin II (TCN2)
P259R polymorphism, assuming a dominant model. As in
our study, no associations were seen for non-synonymous
SNPs in MTHFR, MTHFD1, SHMT1,o rMTR.
SLC19A1 codes for a ubiquitously expressed trans-
membrane protein necessary for the uptake of reduced
folates such as 5-MTHF, the main circulating folate. The
SLC19A1 protein transports 5-MTHF from the lumen of
the gut into the cells of the small intestine and from the
blood stream into epithelial cells. 5-MTHF is the enzy-
matically active form of folate and is required for the
synthesis of methionine from homocysteine, the regenera-
tion of tetrahydrofolate, and nucleotide synthesis [27].
Thus, functional change in the activity of SLC19A1 could
modulate folate metabolism by increasing or decreasing
intracellular folate availability. A plausible role for
SLC19A1 function and colorectal neoplasia risk is sug-
gested by animal studies showing that mice with an inac-
tive gene have an increased susceptibility to chemically
induced CRC [28].
To our knowledge, this is the ﬁrst study of the rela-
tionship between rs1051266 and colorectal adenomas.
However, two previous studies, both also conducted in
non-folic acid-supplemented populations, have reported on
the association between this SNP and colorectal cancer [29,
30]. Contrary to our results (OR = 1.25 (95% CI
1.07–1.45) per A allele), there was no association with
CRC risk in either study population but, unlike our data,
both found a possible decrease in risk associated with the A
allele in those with low folate intake. Further studies of this
SNP in other colorectal adenoma patients will be necessary
before we can draw any conclusions.
Our data are consistent with previous studies of the
association between the MTHFR C677T and A1298C
polymorphisms and colorectal adenoma in suggesting that
neither of these polymorphisms are associated with ade-
noma risk overall [11, 12]. Our data provide limited sup-
port for the hypothesis that the 677 TT genotype may
increase colorectal adenoma risk when folate is low and
decrease risk when folate is high as has been seen in some
studies including our own analysis of the phase 1 subjects
[23, 31–34]. However, our results are consistent with other
studies not reporting such modiﬁcation [35–38].
The data were consistent with a possible U-shaped
relationship between the MTHFR A1298C genotype and
dietary folate intake. A recent European study also
observed an increased adenoma risk for the 1298 CC
genotype and high folate intake [37]. However, our data are
inconsistent with those of most other studies assessing this
interaction for adenoma [36, 39] or colorectal cancer risk
[40–43].
We also observed a signiﬁcant interaction between the
MTHFR 1298 genotype and sex with a decreased risk for
women and an increased risk for men with the CC geno-
type, relative to those with at least one A allele. These
ﬁndings are consistent with those of two other adenoma
studies [37, 39] but opposite to those of a recent CRC study
[44] and inconsistent with studies that did not observe any
modiﬁcation by sex for CRC [45, 46] or rectal cancer [47].
Given these mixed results, future studies should assess
such modiﬁcation so that some consensus can be achieved.
Data from several studies have suggested a gene–gene
interaction between the SLC19A1 G80A and MTHFR
C677T genotypes [29, 48, 49]. In all studies, including our
own, the data suggest that the A allele might be associated
with lower risk in those with the 677 TT genotype.
Although the MTR A2756G polymorphism did not interact
signiﬁcantly with MTHFR C677T, as suggested in some
previous studies [50–54], we did observe nominally sig-
niﬁcant interactions for a set of seven linked MTR SNPs
that may indicate some effect modiﬁcation for this linkage
block, at least in non-Hispanic whites. To our knowledge,
this is the ﬁrst study to suggest such an interaction, and it
remains for future studies to further deﬁne this linkage
block and replicate the interaction before any conclusions
can be drawn.
Ourstudyhasseveralstrengthsincludingthelargesample
size and the comprehensive approach to deﬁning genetic
variation in a large number of folate pathway genes. In
addition, we had data on adenoma risk factors and folate
pathway intermediates including plasma tHcy. Our large
sample size allowed us to conduct several stratiﬁed analyses
withreasonablestatisticalpower,includinganalysesbyrace/
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123ethnic group, folate intake, and alcohol use. Weaknesses of
our study include the fact that we did nothave data on all the
genesrelevanttothefolatepathway.Also,becausethiswasa
sigmoidoscopy-based study, some controls may have had
undetected adenomas in the proximal colon, and so our
ﬁndings are limited to distal adenomas. Additionally, this
study was conducted prior to fortiﬁcation of the US food
supply with folic acid and folate intakes were low compared
to those of supplemented populations. Thus, our ﬁndings
may be speciﬁc to unsupplemented populations. Finally, the
use of a Bonferroni correction for multiple testing in all
stratiﬁed analyses may have been too conservative, and so
there may be some false-negative results. Alternatively,
given the large number of total comparisons made, false-
positive ﬁndings are also possible.
In conclusion, in this comprehensive tagSNP analysis of
11 folate pathway genes, we observed that variation in
SLC19A1 may play a role in colorectal adenoma risk in
non-Hispanic whites. Our data suggest a possible interac-
tion between the MTHFR A1298C genotype and folate
intake as well as an interaction with sex. The SLC19A1
G80A polymorphism and seven SNPs deﬁning a linkage
disequilibrium block in the MTR gene in non-Hispanic
whites may interact with MTHFR C677T genotype in
determining distal colorectal adenoma risk.
Acknowledgments We would like to thank all the subjects who
contributed their time to this study. We would also like to thank Terry
Kolb and Jessie Lin for their assistance with data collection, cleaning,
and management and Anh Diep and for her assistance with bio-
specimen management. This work was supported by the National
Cancer Institute, National Institutes of Health under 1R01 CA096830
and 5P01 CA42710.
Conﬂicts of interest D. Conti is a consultant for Pﬁzer Inc.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Kim YI (2003) Role of folate in colon cancer development and
progression. J Nutr 133:3731S–3739S
2. Giovannucci E (2002) Epidemiologic studies of folate and
colorectal neoplasia: a review. J Nutr 132:2350S–2355S
3. Mason JB, Choi SW (2000) The mechanisms by which folate
depletion enhances colorectal carcinogenesis: a uniﬁed scheme.
Nestle Nutr Workshop Ser Clin Perform Programme 4:87–99;
discussion 99–101
4. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier
RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA
et al (2007) Folic acid for the prevention of colorectal adenomas:
a randomized clinical trial. JAMA 297:2351–2359
5. Song J, Medline A, Mason JB, Gallinger S, Kim YI (2000)
Effects of dietary folate on intestinal tumorigenesis in the apcMin
mouse. Cancer Res 60:5434–5440
6. Song J, Sohn KJ, Medline A, Ash C, Gallinger S, Kim YI (2000)
Chemopreventive effects of dietary folate on intestinal polyps in
Apc ± Msh2-/- mice. Cancer Res 60:3191–3199
7. Nijhout HF, Reed MC, Ulrich CM (2008) Mathematical models
of folate-mediated one-carbon metabolism. Vitam Horm 79:
45–82
8. Ulrich CM, Neuhouser M, Liu AY, Boynton A, Gregory JF III,
Shane B, James SJ, Reed MC, Nijhout HF (2008) Mathematical
modeling of folate metabolism: predicted effects of genetic
polymorphisms on mechanisms and biomarkers relevant to car-
cinogenesis. Cancer Epidemiol Biomarkers Prev 17:1822–1831
9. Ulrich CM (2005) Nutrigenetics in cancer research–folate
metabolism and colorectal cancer. J Nutr 135:2698–2702
10. Xu X, Liu AY, Ulrich CM, Chen J (2009) Folate and cancer:
epidemiological perspective. Taylor and Francis, New York
11. Huang Y, Han S, Li Y, Mao Y, Xie Y (2007) Different roles of
MTHFR C677T and A1298C polymorphisms in colorectal ade-
noma and colorectal cancer: a meta-analysis. J Hum Genet
52:73–85
12. Kono S, Chen K (2005) Genetic polymorphisms of methylene-
tetrahydrofolate reductase and colorectal cancer and adenoma.
Cancer Sci 96:535–542
13. Hazra A, Wu K, Kraft P, Fuchs CS, Giovannucci EL, Hunter DJ
(2007) Twenty-four non-synonymous polymorphisms in the one-
carbon metabolic pathway and risk of colorectal adenoma in the
Nurses’ Health Study. Carcinogenesis 28:1510–1519
14. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006)
XRCC1, XRCC3, and XPD polymorphisms as modiﬁers of the
effect of smoking and alcohol on colorectal adenoma risk. Cancer
Epidemiol Biomarkers Prev 15:2384–2390
15. Stern MC, Siegmund KD, Corral R, Haile RW (2005) XRCC1
and XRCC3 polymorphisms and their role as effect modiﬁers of
unsaturated fatty acids and antioxidant intake on colorectal ade-
nomas risk. Cancer Epidemiol Biomarkers Prev 14:609–615
16. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB,
Willett WC (1992) Reproducibility and validity of an expanded
self-administered semiquantitative food frequency questionnaire
amongmalehealthprofessionals.AmJEpidemiol135:1114–1126;
discussion 1127–1136
17. StramDO,Hankin JH,WilkensLR,PikeMC,MonroeKR,ParkS,
Henderson BE, Nomura AM, Earle ME, Nagamine FS et al (2000)
Calibration of the dietary questionnaire for a multiethnic cohort in
Hawaii and Los Angeles. Am J Epidemiol 151:358–370
18. Bird CL, Swendseid ME, Witte JS, Shikany JM, Hunt IF, Frankl
HD, Lee ER, Longnecker MP, Haile RW (1995) Red cell and
plasma folate, folate consumption, and the risk of colorectal
adenomatous polyps. Cancer Epidemiol Biomarkers Prev
4:709–714
19. Kuo K, Still R, Cale S, McDowell I (1997) Standardization
(external and internal) of HPLC assay for plasma homocysteine.
Clin Chem 43:1653–1655
20. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis
and visualization of LD and haplotype maps. Bioinformatics
21:263–265
21. Shen R, Fan JB, Campbell D, Chang W, Chen J, Doucet D,
Yeakley J, Bibikova M, Wickham Garcia E, McBride C et al
(2005) High-throughput SNP genotyping on universal bead
arrays. Mutat Res 573:70–82
22. Consortium TIH (2005) A haplotype map of the human genome.
Nature 437:1299–1320
23. Levine AJ, Siegmund KD, Ervin CM, Diep A, Lee ER, Frankl
HD, Haile RW (2000) The methylenetetrahydrofolate reductase
550 Cancer Causes Control (2011) 22:541–552
123677C?T polymorphism and distal colorectal adenoma risk.
Cancer Epidemiol Biomarkers Prev 9:657–663
24. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews
RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP
et al (1995) A candidate genetic risk factor for vascular disease: a
common mutation in methylenetetrahydrofolate reductase. Nat
Genet 10:111–113
25. Li Y, Abecasis GR (2006) Mach 1.0: rapid haplotype recon-
struction and missing genotype inference. Am J Hum Genet
S79:2290
26. Conneely KN, Boehnke M (2007) So many correlated tests, so
little time! Rapid adjustment of p values for multiple correlated
tests. Am J Hum Genet 81:1158–1168
27. Lucock M (2000) Folic acid: nutritional biochemistry, molecular
biology, and role in disease processes. Mol Genet Metab
71:121–138
28. Ma DW, Finnell RH, Davidson LA, Callaway ES, Spiegelstein O,
Piedrahita JA, Salbaum JM, Kappen C, Weeks BR, James J et al
(2005) Folate transport gene inactivation in mice increases sen-
sitivity to colon carcinogenesis. Cancer Res 65:887–897
29. Eklof V, Van Guelpen B, Hultdin J, Johansson I, Hallmans G,
Palmqvist R (2008) The reduced folate carrier (RFC1) 80G[A
and folate hydrolase 1 (FOLH1) 1561C[T polymorphisms and
the risk of colorectal cancer: a nested case-referent study. Scand J
Clin Lab Invest 68:393–401
30. Ulrich CM, Curtin K, Potter JD, Bigler J, Caan B, Slattery ML
(2005) Polymorphisms in the reduced folate carrier, thymidylate
synthase, or methionine synthase and risk of colon cancer. Cancer
Epidemiol Biomarkers Prev 14:2509–2516
31. Boyapati SM, Bostick RM, McGlynn KA, Fina MF, Roufail WM,
Geisinger KR, Hebert JR, Coker A, Wargovich M (2004) Folate
intake, MTHFR C677T polymorphism, alcohol consumption, and
risk for sporadic colorectal adenoma (United States). Cancer
Causes Control 15:493–501
32. Marugame T, Tsuji E, Kiyohara C, Eguchi H, Oda T, Shinchi K,
Kono S (2003) Relation of plasma folate and methylenetetrahy-
drofolate reductase C677T polymorphism to colorectal adeno-
mas. Int J Epidemiol 32:64–66
33. Ulrich CM, Kampman E, Bigler J, Schwartz SM, Chen C,
Bostick R, Fosdick L, Beresford SA, Yasui Y, Potter JD (1999)
Colorectal adenomas and the C677T MTHFR polymorphism:
evidence for gene-environment interaction? Cancer Epidemiol
Biomarkers Prev 8:659–668
34. Ulvik A, Evensen ET, Lien EA, Hoff G, Vollset SE, Majak BM,
Ueland PM (2001) Smoking, folate and methylenetetrahy-
drofolate reductase status as interactive determinants of ade-
nomatous and hyperplastic polyps of colorectum. Am J Med
Genet 101:246–254
35. Chen J, Giovannucci E, Hankinson SE, Ma J, Willett WC,
Spiegelman D, Kelsey KT, Hunter DJ (1998) A prospective study
of methylenetetrahydrofolate reductase and methionine synthase
gene polymorphisms, and risk of colorectal adenoma. Carcino-
genesis 19:2129–2132
36. Giovannucci E, Chen J, Smith-Warner SA, Rimm EB, Fuchs CS,
Palomeque C, Willett WC, Hunter DJ (2003) Methylenetetrahy-
drofolate reductase, alcohol dehydrogenase, diet, and risk of
colorectal adenomas. Cancer Epidemiol Biomarkers Prev
12:970–979
37. Lightfoot TJ, Barrett JH, Bishop T, Northwood EL, Smith G,
Wilkie MJ, Steele RJ, Carey FA, Key TJ, Wolf R et al (2008)
Methylene tetrahydrofolate reductase genotype modiﬁes the che-
mopreventive effect of folate in colorectal adenoma, but not colo-
rectal cancer. Cancer Epidemiol Biomarkers Prev 17:2421–2430
38. van den Donk M, Buijsse B, van den Berg SW, Ocke MC,
Harryvan JL, Nagengast FM, Kok FJ, Kampman E (2005)
Dietary intake of folate and riboﬂavin, MTHFR C677T genotype,
and colorectal adenoma risk: a Dutch case–control study. Cancer
Epidemiol Biomarkers Prev 14:1562–1566
39. Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ,
Atkin WS, Macklin CP, Cecil T, Bishop TD, Primrose J et al
(2006) MTHFR (C677T and A1298C) polymorphisms and risk of
sporadic distal colorectal adenoma in the UK ﬂexible sigmoid-
oscopy screening trial (United Kingdom). Cancer Causes Control
17:793–801
40. Curtin K, Bigler J, Slattery ML, Caan B, Potter JD, Ulrich CM
(2004) MTHFR C677T and A1298C polymorphisms: diet,
estrogen, and risk of colon cancer. Cancer Epidemiol Biomarkers
Prev 13:285–292
41. Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscocho L,
Martin C, Sandler R (2002) 5,10-Methylenetetrahydrofolate
reductase codon 677 and 1298 polymorphisms and colon cancer
in African Americans and whites. Cancer Epidemiol Biomarkers
Prev 11:1611–1621
42. Matsuo K, Ito H, Wakai K, Hirose K, Saito T, Suzuki T, Kato T,
Hirai T, Kanemitsu Y, Hamajima H et al (2005) One-carbon
metabolism related gene polymorphisms interact with alcohol
drinking to inﬂuence the risk of colorectal cancer in Japan.
Carcinogenesis 26:2164–2171
43. Otani T, Iwasaki M, Hanaoka T, Kobayashi M, Ishihara J,
Natsukawa S, Shaura K, Koizumi Y, Kasuga Y, Yoshimura K
et al (2005) Folate, vitamin B6, vitamin B12, and vitamin B2
intake, genetic polymorphisms of related enzymes, and risk of
colorectal cancer in a hospital-based case–control study in Japan.
Nutr Cancer 53:42–50
44. Koushik A, Kraft P, Fuchs CS, Hankinson SE, Willett WC,
Giovannucci EL, Hunter DJ (2006) Nonsynonymous polymor-
phisms in genes in the one-carbon metabolism pathway and
associations with colorectal cancer. Cancer Epidemiol Biomark-
ers Prev 15:2408–2417
45. Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK,
Albertsen H, Potter JD, Samowitz WS (2007) Genetic polymor-
phisms in one-carbon metabolism: associations with CpG island
methylator phenotype (CIMP) in colon cancer and the modifying
effects of diet. Carcinogenesis 28:1672–1679
46. Yin G, Kono S, Toyomura K, Hagiwara T, Nagano J, Mizoue T,
Mibu R, Tanaka M, Kakeji Y, Maehara Y et al (2004) Methy-
lenetetrahydrofolate reductase C677T and A1298C polymor-
phisms and colorectal cancer: the Fukuoka colorectal cancer
study. Cancer Sci 95:908–913
47. Murtaugh MA, Curtin K, Sweeney C, Wolff RK, Holubkov R,
Caan BJ, Slattery ML (2007) Dietary intake of folate and
co-factors in folate metabolism, MTHFR polymorphisms, and
reduced rectal cancer. Cancer Causes Control 18:153–163
48. Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pﬁster M,
Rosenblatt DS, Nicolas JP (2000) A polymorphism (80G?A) in
the reduced folate carrier gene and its associations with folate
status and homocysteinemia. Mol Genet Metab 70:310–315
49. Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH (2006)
Interactions among polymorphisms in folate-metabolizing genes
and serum total homocysteine concentrations in a healthy elderly
population. Am J Clin Nutr 83:708–713
50. Feix A, Fritsche-Polanz R, Kletzmayr J, Vychytil A, Horl WH,
Sunder-Plassmann G, Fodinger M (2001) Increased prevalence of
combined MTR and MTHFR genotypes among individuals with
severely elevated total homocysteine plasma levels. Am J Kidney
Dis 38:956–964
Cancer Causes Control (2011) 22:541–552 551
12351. Gross M, Friedman G, Eliashar R, Koren-Morag N, Goldschmidt
N, Atta IA, Ben-Yehuda A (2006) Impact of methionine synthase
gene and methylenetetrahydrofolate reductase gene polymor-
phisms on the risk of sudden sensorineural hearing loss. Audiol
Neurootol 11:287–293
52. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR,
Seifried A (2002) B-vitamin intake, metabolic genes, and colo-
rectal cancer risk (United States). Cancer Causes Control
13:239–248
53. Mostowska A, Hozyasz KK, Wojcicki P, Dziegelewska M,
Jagodzinski PP (2009) Associations of folate and choline
metabolism gene polymorphisms with orofacial clefts. J Med
Genet 47:809–815
54. Terruzzi I, Senesi P, Fermo I, Lattuada G, Luzi L (2007) Are
genetic variants of the methyl group metabolism enzymes risk
factors predisposing to obesity? J Endocrinol Invest 30:747–753
552 Cancer Causes Control (2011) 22:541–552
123